Alastair Robertson - Resmed Chief Officer
| RMD Stock | 38.59 0.48 1.26% |
Executive
Alastair Robertson is Chief Officer of Resmed Inc DRC
| Address | 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123 |
| Phone | 858-836-5000 |
| Web | https://www.resmed.com |
Resmed Management Efficiency
The company has return on total asset (ROA) of 0.1327 % which means that it generated a profit of $0.1327 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2357 %, meaning that it generated $0.2357 on every $100 dollars invested by stockholders. Resmed's management efficiency ratios could be used to measure how well Resmed manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Resmed's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 7.2 B in 2024, whereas Change To Liabilities is likely to drop slightly above 24.6 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dominic Horsley | Computershare | N/A | |
| Josie Shawcross | Embark Education Group | N/A | |
| Craig Thomas | Computershare | N/A | |
| Nick Oldfield | Computershare | N/A | |
| Martin Cummings | Aurelia Metals | N/A | |
| John Britten | Computershare | N/A | |
| Bev Davies | Embark Education Group | N/A | |
| Henry Blundell | Embark Education Group | N/A | |
| Martin MBA | Carawine Resources Limited | N/A | |
| Matthew Nuttall | Aurelia Metals | N/A | |
| Susan Scheepers | Aurelia Metals | N/A | |
| Francis Catterall | Computershare | N/A | |
| Hussain Baig | Computershare | 52 | |
| Peter Belval | Computershare | N/A | |
| Jenny Aldous | Embark Education Group | N/A | |
| Matt Veal | Embark Education Group | N/A | |
| Tomas Stehlik | Embark Education Group | N/A | |
| Angus Wyllie | Aurelia Metals | N/A | |
| Rochelle Carey | Aurelia Metals | N/A | |
Management Performance
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.13 |
Resmed Inc DRC Leadership Team
Elected by the shareholders, the Resmed's board of directors comprises two types of representatives: Resmed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Resmed. The board's role is to monitor Resmed's management team and ensure that shareholders' interests are well served. Resmed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Resmed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| AM BE, Chair Founder | ||
| Justin Leong, Chief Officer | ||
| Michael Rider, Chief Secretary | ||
| Robert Douglas, Special Advisor | ||
| Vered Keisar, Chief Officer | ||
| Carlos MD, Chief Officer | ||
| Kaushik Ghoshal, Chief SaaS | ||
| YvonneKatrin Pucknat, Chief Officer | ||
| Michael Fliss, Chief Officer | ||
| Amy Wakeham, VP Communications | ||
| Brett Sandercock, Chief Officer | ||
| BE MBA, CEO Director | ||
| AM AM, Founder Chairman | ||
| David Pendarvis, Global Officer | ||
| Jim Ellis, Chief Officer | ||
| Alastair Robertson, Chief Officer | ||
| Constance Bienfait, Director Relations | ||
| Hemanth Reddy, Chief Officer | ||
| Urvashi Tyagi, Chief Officer | ||
| Dawn Haake, Chief Officer | ||
| Todd Friedman, Chief Officer |
Resmed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Resmed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 57.19 B | ||||
| Shares Outstanding | 1.47 B | ||||
| Shares Owned By Institutions | 10.51 % | ||||
| Price To Book | 7.06 X | ||||
| Price To Sales | 11.73 X | ||||
| Revenue | 4.69 B |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Resmed Stock Analysis
When running Resmed's price analysis, check to measure Resmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Resmed is operating at the current time. Most of Resmed's value examination focuses on studying past and present price action to predict the probability of Resmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Resmed's price. Additionally, you may evaluate how the addition of Resmed to your portfolios can decrease your overall portfolio volatility.